Human Genome Epidemiology Literature Finder
Records 1 - 6 (of 6 Records) |
Query Trace: Weight Gain and CYP1A2[original query] |
---|
Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry research 2008 Dec 161 (3): 275-83. Thomas Pramod, Srivastava Vibhuti, Singh Anuradha, Mathur Priya, Nimgaonkar Vishwajit L, Lerer Bernard, Thelma B K, Deshpande Smita |
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The pharmacogenomics journal 2010 Feb 10 (1): 20-9. Laika B, Leucht S, Heres S, Schneider H, Steimer |
CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Therapeutic drug monitoring 2015 Apr 37 (2): 152-60. Czerwensky Fabian, Leucht Stefan, Steimer Wern |
Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2016 Sep . Vasudev Kamini, Choi Yun-Hee, Norman Ross, Kim Richard B, Schwarz Ute |
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in pharmacology 2021 8 12 711940. Soria-Chacartegui Paula, Villapalos-García Gonzalo, Zubiaur Pablo, Abad-Santos Francisco, Koller Do |
Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. Pharmaceuticals (Basel, Switzerland) 2022 6 15 (6): . Merino Diane, Fernandez Arnaud, Gérard Alexandre O, Ben Othman Nouha, Rocher Fanny, Askenazy Florence, Verstuyft Céline, Drici Milou-Daniel, Thümmler Susan |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: